Figure S1. Treatment with OBP-801 or amrubicin inhibits the viability of human lung cancer cell lines. (A) H520 human SQCLC cells were treated with various concentrations of OBP-801 or amrubicin. After 72 h, cell viability was assessed by the CCK-8 assay. (B) Human lung adenocarcinoma A549 cells were treated with various concentrations of OBP-801 or amrubicin. After 72 h, cell viability was assessed by the CCK-8 assay. Data are presented as the mean ± SD from three independent experiments. CCK-8, Cell Counting Kit-8; SQCLC, squamous cell lung carcinoma.



Figure S2. Combined treatment with OBP-801 and doxorubicin inhibits the viability of Calu-1 human squamous cell lung carcinoma cells. Calu-1 cells were treated with 2.75 nM OBP-801 with or without 1.5 μM doxorubicin. After 72 h, cell viability was assessed by the Cell Counting Kit-8 assay. Data are presented as the mean ± SD from three independent experiments; $^{**}P<0.01$.



Figure S3. Representative histograms of flow cytometry analysis of treated Calu-1 human squamous cell lung carcinoma cells in Fig. 2A.



Figure S4. Representative histograms of flow cytometry analysis of treated Calu-1 human squamous cell lung carcinoma cells in Fig. 2C.



Figure S5. Representative histograms of flow cytometry analysis of treated H520 human squamous cell lung carcinoma cells in Fig. 2C.



Figure S6. Representative histograms of flow cytometry analysis of treated A549 human lung adenocarcinoma cells in Fig. 2C.



Figure S7. Representative histograms of flow cytometry analysis in Fig. 3A.



Figure S8. Representative histograms of flow cytometry analysis in Fig. 3B.



Figure S9. Representative histograms of flow cytometry analysis in Fig. 3C.



Figure S10. Representative histograms of flow cytometry analysis in Fig. 4A.



Figure S11. Representative histograms of flow cytometry analysis in Fig. 5B.